You are here

  • Home
  • Archive
  • Volume 4, Issue Suppl 1
  • 88 Ixazomib, an oral proteasome inhibitor, depletes plasma cells reducing autoantibodies and pdcs in pre-clinical model of systemic lupus erythematosus

Citation Tools

Article menu

Download PDFPDF

Poster Session
New therapies and therapeutic targets – SLE
88 Ixazomib, an oral proteasome inhibitor, depletes plasma cells reducing autoantibodies and pdcs in pre-clinical model of systemic lupus erythematosus
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Itomi Y, Tanaka T, Sagara M, et al
88 Ixazomib, an oral proteasome inhibitor, depletes plasma cells reducing autoantibodies and pdcs in pre-clinical model of systemic lupus erythematosus
Lupus Science & Medicine 2017;4:doi: 10.1136/lupus-2017-000215.88